319 related articles for article (PubMed ID: 30672082)
1. Cost-effectiveness analysis of screen-and-treat strategy in asymptomatic Chinese for preventing Helicobacter pylori-associated diseases.
Chen Q; Liang X; Long X; Yu L; Liu W; Lu H
Helicobacter; 2019 Apr; 24(2):e12563. PubMed ID: 30672082
[TBL] [Abstract][Full Text] [Related]
2. Both family-based Helicobacter pylori infection control and management strategy and screen-and-treat strategy are cost-effective for gastric cancer prevention.
Ma J; Yu M; Shao QQ; Yu XC; Zhang C; Zhao JB; Yuan L; Qi YB; Hu RB; Wei PR; Xiao W; Chen Q; Jia BL; Chen CL; Lu H; Ding SZ
Helicobacter; 2022 Aug; 27(4):e12911. PubMed ID: 35706404
[TBL] [Abstract][Full Text] [Related]
3. The cost-effectiveness of population Helicobacter pylori screening and treatment: a Markov model using economic data from a randomized controlled trial.
Mason J; Axon AT; Forman D; Duffett S; Drummond M; Crocombe W; Feltbower R; Mason S; Brown J; Moayyedi P;
Aliment Pharmacol Ther; 2002 Mar; 16(3):559-68. PubMed ID: 11876711
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of population screening for Helicobacter pylori in preventing gastric cancer and peptic ulcer disease, using simulation.
Roderick P; Davies R; Raftery J; Crabbe D; Pearce R; Patel P; Bhandari P
J Med Screen; 2003; 10(3):148-56. PubMed ID: 14561268
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of Helicobacter pylori "test and treat" for patients with typical reflux symptoms in a population with a high prevalence of H. pylori infection: a Markov model analysis.
You JH; Wong PL; Wu JC
Scand J Gastroenterol; 2006 Jan; 41(1):21-9. PubMed ID: 16373272
[TBL] [Abstract][Full Text] [Related]
6. Clinical and economic effects of population-based Helicobacter pylori screening to prevent gastric cancer.
Fendrick AM; Chernew ME; Hirth RA; Bloom BS; Bandekar RR; Scheiman JM
Arch Intern Med; 1999 Jan; 159(2):142-8. PubMed ID: 9927096
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of
Kowada A
Scand J Gastroenterol; 2019 Jun; 54(6):685-689. PubMed ID: 31190581
[No Abstract] [Full Text] [Related]
8. [Dyspepsia and Helicobacter pylori infection in employees of a large industry. Results of a prospective BASF Helicobacter pylori prevention campaign].
Schilling D; Messerer P; Ott MG; Schauwecker P; Zober A; Riemann JF
Med Klin (Munich); 2002 Jan; 97(1):6-11. PubMed ID: 11831064
[TBL] [Abstract][Full Text] [Related]
9. Helicobacter pylori "Test-and-Treat" strategy with urea breath test: A cost-effective strategy for the management of dyspepsia and the prevention of ulcer and gastric cancer in Spain-Results of the Hp-Breath initiative.
Beresniak A; Malfertheiner P; Franceschi F; Liebaert F; Salhi H; Gisbert JP
Helicobacter; 2020 Aug; 25(4):e12693. PubMed ID: 32285569
[TBL] [Abstract][Full Text] [Related]
10. Cost effectiveness analysis of population-based serology screening and (13)C-Urea breath test for Helicobacter pylori to prevent gastric cancer: a markov model.
Xie F; Luo N; Lee HP
World J Gastroenterol; 2008 May; 14(19):3021-7. PubMed ID: 18494053
[TBL] [Abstract][Full Text] [Related]
11. Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials.
Parsonnet J; Harris RA; Hack HM; Owens DK
Lancet; 1996 Jul; 348(9021):150-4. PubMed ID: 8684154
[TBL] [Abstract][Full Text] [Related]
12. Using stool antigen to screen for Helicobacter pylori in immigrants and refugees from high prevalence countries is relatively cost effective in reducing the burden of gastric cancer and peptic ulceration.
Schulz TR; McBryde ES; Leder K; Biggs BA
PLoS One; 2014; 9(9):e108610. PubMed ID: 25268809
[TBL] [Abstract][Full Text] [Related]
13. Economic and health impacts of Helicobacter pylori eradication strategy for the treatment of peptic ulcer disease: A cost-effectiveness analysis.
Kowada A; Asaka M
Helicobacter; 2022 Jun; 27(3):e12886. PubMed ID: 35343031
[TBL] [Abstract][Full Text] [Related]
14. The health economics of Helicobacter pylori infection.
Moayyedi P
Best Pract Res Clin Gastroenterol; 2007; 21(2):347-61. PubMed ID: 17382282
[TBL] [Abstract][Full Text] [Related]
15. Cost-benefit analysis of testing for Helicobacter pylori in dyspeptic subjects.
Sonnenberg A
Am J Gastroenterol; 1996 Sep; 91(9):1773-7. PubMed ID: 8792696
[TBL] [Abstract][Full Text] [Related]
16. [Helicobacter pylori: screen and treat?].
Malfertheiner P
Dtsch Med Wochenschr; 2014 May; 139(17):905-8. PubMed ID: 24760696
[TBL] [Abstract][Full Text] [Related]
17. Economic and health impacts of introducing Helicobacter pylori eradication strategy into national gastric cancer policy in Japan: A cost-effectiveness analysis.
Kowada A; Asaka M
Helicobacter; 2021 Oct; 26(5):e12837. PubMed ID: 34278663
[TBL] [Abstract][Full Text] [Related]
18. A screening program to test and treat for Helicobacter pylori infection: Cost-utility analysis by age, sex and ethnicity.
Teng AM; Kvizhinadze G; Nair N; McLeod M; Wilson N; Blakely T
BMC Infect Dis; 2017 Feb; 17(1):156. PubMed ID: 28219322
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of Helicobacter pylori screening followed by eradication treatment for employees in Japan.
Kowada A
Epidemiol Infect; 2018 Oct; 146(14):1834-1840. PubMed ID: 30056808
[TBL] [Abstract][Full Text] [Related]
20. Cost-Effectiveness Analysis of the Helicobacter Pylori Screening Programme in an Asymptomatic Population in China.
Feng T; Zheng Z; Xu J; Cao P; Gao S; Yu X
Int J Environ Res Public Health; 2022 Aug; 19(16):. PubMed ID: 36011621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
